Cosmo plots $107M IPO for skin business; Bluebird picks a new CSO;

@FierceBiotech: Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Bluebird bio builds its case for gene therapy as first sickle cell patient responds. Article | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> Italy's Cosmo Pharmaceuticals is planning to spin off its dermatology business, Cassiopea, in a European IPO. The drugmaker expects to raise more than 100 million Swiss francs ($107 million) in the deal, Chief Financial Officer Christoph Tanner told Bloomberg. Anything less and "I would fire myself and everybody else," he said. News

> Bluebird bio ($BLUE) has recruited Philip Gregory, former Sangamo BioSciences ($SGMO) chief scientific officer, to take the same position on its staff. More

> The FDA accepted Teva's ($TEVA) application for reslizumab, an antibody designed to treat severe asthma, and promises to make a final decision on the injection by March 2016. GlaxoSmithKline's ($GSK) similar mepolizumab is up for approval by Nov. 4. Item

Medical Device News

@FierceMedDev: ICYMI Friday: Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI Friday: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: India's PM is facing pushback from MSF over access to generic drugs. More from Reuters| Follow @EmilyWFierce

> FDA approves St. Jude's neurostimulator for Parkinson's, setting up rivalry with Medtronic. Report

> Milestone Pharma raises $17M Series B for Phase II of at-home, drug-device cardiac arrhythmia combo. Story

> Study: Researchers find dual-hormone artificial pancreas best for treating nocturnal hypoglycemia. Article

Pharma News

@FiercePharma: G7 vows to combat antibiotics resistance, but animal health groups urge caution. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce:  | Follow @EricPFierce

@CarlyHFierce: ICYMI: Consumer group demands FDA correct 'compounded mistake' on Vanda's Hetlioz label. Report | Follow @CarlyHFierce

> Branded pharma worries, generics makers cheer as trade pact hits snag in Congress. Article

> FDA taps PatientsLikeMe to harness patient info for drug-safety monitoring. News

Animal Health News

> AB Science struggles to break out as canine cancer drug flounders. Report

> Rapamycin raises $2.5M to advance lead drug for treating cancer in pets. Item

> G7 vows to combat antibiotics resistance, but animal health groups urge caution. More

> Scientists scrambling to determine if virulent avian flu is airborne. Story

> Lilly quashes rumors of Elanco spinoff as stock soars. Article

Biotech IT News

> EHR-enabled data dive links stomach blockbusters to heart attacks. More

> Allergan slashes laptop use in full-throttle mobile push. Report

> Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact. Story

> The search for exceptional responders in tumor sequencing databases. Item

> J&J teams with Emulate to use organ-on-a-chip technology in R&D programs. Article

Pharma Marketing News

> PatientsLikeMe, FDA partner up to track online drug safety clues. Item

> CoheroHealth's 'smart,' mobile spirometer begins pilots with pharma, payers. News

> Experts urge FDA to step in to quash 'Low-T' awareness efforts. More

> Merck ramps up Belsomra marketing, hoping to wake up a sleepy insomnia market. Story

> Mannkind investors skittish after CEO, CFO update on Afrezza launch. Article

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.